APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Cytomegalovirus Envelope Glycoprotein B

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Cytomegalovirus Envelope Glycoprotein B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025183 pages

Choose your research edition.

Industry ResearchHuman Cytomegalovirus Envelope Glycoprotein B Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Cytomegalovirus Envelope Glycoprotein B Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Human Cytomegalovirus Envelope Glycoprotein B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Cytomegalovirus Envelope Glycoprotein B Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Human Cytomegalovirus Envelope Glycoprotein B market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Vical Incorporated, VBI Vaccine Inc, Vakzine Projekt Management GmbH, Trellis Bioscience, Inc. and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Cytomegalovirus Envelope Glycoprotein B market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Cytomegalovirus Envelope Glycoprotein B and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Cytomegalovirus Envelope Glycoprotein B sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Cytomegalovirus Envelope Glycoprotein B market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Company

Vical Incorporated

VBI Vaccine Inc

Vakzine Projekt Management GmbH

Trellis Bioscience, Inc.

Astellas Pharma Inc.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Type

CSJ-148

CyMVectin

PPCM

TRL-345

Cytomegalovirus Vaccine

Others

Human Cytomegalovirus Envelope Glycoprotein B Segment by Application

Infectious Disease

Women's Health

Oncology

Others

Human Cytomegalovirus Envelope Glycoprotein B Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Cytomegalovirus Envelope Glycoprotein B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Cytomegalovirus Envelope Glycoprotein B and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Cytomegalovirus Envelope Glycoprotein B.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Cytomegalovirus Envelope Glycoprotein B market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Cytomegalovirus Envelope Glycoprotein B Industry Trends Table 2. Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers Table 3. Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges Table 4. Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints Table 5. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Manufacturers Table 9. Global Human Cytomegalovirus Envelope Glycoprotein B Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human Cytomegalovirus Envelope Glycoprotein B Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Cytomegalovirus Envelope Glycoprotein B Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Cytomegalovirus Envelope Glycoprotein B Manufacturers, Product Type & Application Table 13. Global Human Cytomegalovirus Envelope Glycoprotein B Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Cytomegalovirus Envelope Glycoprotein B by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CSJ-148 Table 17. Major Manufacturers of CyMVectin Table 18. Major Manufacturers of PPCM Table 19. Major Manufacturers of TRL-345 Table 20. Major Manufacturers of Cytomegalovirus Vaccine Table 21. Major Manufacturers of Others Table 22. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021-2026) & (W Units) Table 24. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2027-2032) & (W Units) Table 25. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2021-2026) Table 26. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2027-2032) Table 27. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2021-2026) & (W Units) Table 29. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2027-2032) & (W Units) Table 30. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2021-2026) Table 31. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Infectious Disease Table 33. Major Manufacturers of Women's Health Table 34. Major Manufacturers of Oncology Table 35. Major Manufacturers of Others Table 36. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021-2026) & (W Units) Table 38. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2027-2032) & (W Units) Table 39. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2021-2026) Table 40. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2027-2032) Table 41. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 42. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2021-2026) & (W Units) Table 43. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2027-2032) & (W Units) Table 44. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2021-2026) Table 45. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2027-2032) Table 46. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2021-2026) & (W Units) Table 48. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Region (2021-2026) Table 49. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Forecasted by Region (2027-2032) & (W Units) Table 50. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026) & (W Units) Table 53. North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032) & (W Units) Table 54. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026) & (W Units) Table 56. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032) & (W Units) Table 57. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026) & (W Units) Table 59. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032) & (W Units) Table 60. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2026) & (W Units) Table 62. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2027-2032) & (W Units) Table 63. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Region (2021-2026) Table 67. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Region (2027-2032) Table 68. Vical Incorporated Company Information Table 69. Vical Incorporated Business Overview Table 70. Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 72. Vical Incorporated Recent Development Table 73. VBI Vaccine Inc Company Information Table 74. VBI Vaccine Inc Business Overview Table 75. VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 77. VBI Vaccine Inc Recent Development Table 78. Vakzine Projekt Management GmbH Company Information Table 79. Vakzine Projekt Management GmbH Business Overview Table 80. Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 82. Vakzine Projekt Management GmbH Recent Development Table 83. Trellis Bioscience, Inc. Company Information Table 84. Trellis Bioscience, Inc. Business Overview Table 85. Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 87. Trellis Bioscience, Inc. Recent Development Table 88. Astellas Pharma Inc. Company Information Table 89. Astellas Pharma Inc. Business Overview Table 90. Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio Table 92. Astellas Pharma Inc. Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Human Cytomegalovirus Envelope Glycoprotein B Distributors List Table 96. Human Cytomegalovirus Envelope Glycoprotein B Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Human Cytomegalovirus Envelope Glycoprotein B Product Image Figure 2. Global Human Cytomegalovirus Envelope Glycoprotein B Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Cytomegalovirus Envelope Glycoprotein B Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Cytomegalovirus Envelope Glycoprotein B Sales (2021-2032) & (W Units) Figure 5. Global Human Cytomegalovirus Envelope Glycoprotein B Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Cytomegalovirus Envelope Glycoprotein B Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CSJ-148 Image Figure 9. CyMVectin Image Figure 10. PPCM Image Figure 11. TRL-345 Image Figure 12. Cytomegalovirus Vaccine Image Figure 13. Others Image Figure 14. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2021-2032) Figure 17. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2021-2032) Figure 20. Infectious Disease Image Figure 21. Women's Health Image Figure 22. Oncology Image Figure 23. Others Image Figure 24. Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2021-2032) Figure 27. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2021-2032) Figure 30. North America Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 31. North America Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2021-2032) Figure 32. U.S. Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Canada Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2021-2032) Figure 37. Germany Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 38. France Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 39. U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Italy Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2021-2032) Figure 44. China Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Japan Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 48. India Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Australia Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Country (2021-2032) Figure 52. Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South Africa Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 57. UAE Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Chile Human Cytomegalovirus Envelope Glycoprotein B Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032) & (US$ Million) Figure 63. North America Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032) & (US$ Million) Figure 65. Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Human Cytomegalovirus Envelope Glycoprotein B Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • CSJ-148
  • CyMVectin
  • PPCM
  • TRL-345
  • Cytomegalovirus Vaccine
  • Others
Applications
  • Infectious Disease
  • Women's Health
  • Oncology
  • Others
Companies covered
  • Vical Incorporated
  • VBI Vaccine Inc
  • Vakzine Projekt Management GmbH
  • Trellis Bioscience, Inc.
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
  1. 2.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
  2. 2.2 Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers
  3. 2.3 Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges
  4. 2.4 Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints
3 Human Cytomegalovirus Envelope Glycoprotein B Market by Manufacturers
  1. 3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Cytomegalovirus Envelope Glycoprotein B Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Cytomegalovirus Envelope Glycoprotein B Manufacturers, Product Type & Application
  7. 3.7 Global Human Cytomegalovirus Envelope Glycoprotein B Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Cytomegalovirus Envelope Glycoprotein B Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Cytomegalovirus Envelope Glycoprotein B Tier 1, Tier 2, and Tier 3
4 Human Cytomegalovirus Envelope Glycoprotein B Market by Type
  1. 4.1 Human Cytomegalovirus Envelope Glycoprotein B Type Introduction
  2. 4.1.1 CSJ-148
  3. 4.1.2 CyMVectin
  4. 4.1.3 PPCM
  5. 4.1.4 TRL-345
  6. 4.1.5 Cytomegalovirus Vaccine
  7. 4.1.6 Others
  8. 4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type
  9. 4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021-2032)
  11. 4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2021-2032)
  12. 4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type
  13. 4.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2021-2032)
  15. 4.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2021-2032)
5 Human Cytomegalovirus Envelope Glycoprotein B Market by Application
  1. 5.1 Human Cytomegalovirus Envelope Glycoprotein B Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Women's Health
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application
  7. 5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021-2032)
  9. 5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2021-2032)
  10. 5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application
  11. 5.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2021-2032)
  13. 5.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2021-2032)
6 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region
  1. 6.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2021-2032)
  3. 6.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2021-2026)
  4. 6.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region
  1. 7.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region
  2. 7.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032)
  8. 7.2.2 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032)
  11. 7.3.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Vical Incorporated
  2. 8.1.1 Vical Incorporated Company Information
  3. 8.1.2 Vical Incorporated Business Overview
  4. 8.1.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  6. 8.1.5 Vical Incorporated Recent Developments
  7. 8.2 VBI Vaccine Inc
  8. 8.2.1 VBI Vaccine Inc Company Information
  9. 8.2.2 VBI Vaccine Inc Business Overview
  10. 8.2.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  12. 8.2.5 VBI Vaccine Inc Recent Developments
  13. 8.3 Vakzine Projekt Management GmbH
  14. 8.3.1 Vakzine Projekt Management GmbH Company Information
  15. 8.3.2 Vakzine Projekt Management GmbH Business Overview
  16. 8.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  18. 8.3.5 Vakzine Projekt Management GmbH Recent Developments
  19. 8.4 Trellis Bioscience, Inc.
  20. 8.4.1 Trellis Bioscience, Inc. Company Information
  21. 8.4.2 Trellis Bioscience, Inc. Business Overview
  22. 8.4.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  24. 8.4.5 Trellis Bioscience, Inc. Recent Developments
  25. 8.5 Astellas Pharma Inc.
  26. 8.5.1 Astellas Pharma Inc. Company Information
  27. 8.5.2 Astellas Pharma Inc. Business Overview
  28. 8.5.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
  30. 8.5.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Cytomegalovirus Envelope Glycoprotein B Value Chain Analysis
  2. 9.1.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process
  6. 9.2 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
  9. 9.2.3 Human Cytomegalovirus Envelope Glycoprotein B Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst